Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01941836 · ClinicalTrials.gov registry record · Phase 2

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

A Phase 2 study of Hypercholesterolemia, sponsored by Esperion Therapeutics.

Completed
Registry status
Phase 2
Development phase
349
Enrollment target
20
Study locations

NCT01941836 is a Phase 2 study of Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 349 participants, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01941836, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
349 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.

Conditions Studied

Hypercholesterolemia

Interventions

  • DRUG Ezetimibe
  • DRUG ETC-1002

Study Locations (20)

California

  • - Beverly Hills
  • - Chino
  • - Lincoln
  • - Long Beach
  • - Los Angeles
  • - Newport Beach
  • - Thousand Oaks
  • - Vista

Florida

  • - Atlantis
  • - Brandon
  • - Hialeah
  • - Jacksonville
  • - Oviedo
  • - Ponte Vedra
  • - Port Orange

Alabama

  • - Birmingham
  • - Muscle Shoals

Arizona

  • - Chandler

Colorado

  • - Denver

Connecticut

  • - Hartford

Trial Details

FieldValue
Enrollment Target 349 participants
Start Date 2013-09
Est. Completion 2014-11
Phase Phase 2

Sponsor

Esperion Therapeutics

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01941836

The ClinicalTrials.gov registry entry for NCT01941836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower). The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Ezetimibe is the first listed.

NCT01941836 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT01941836 about?

NCT01941836 is a clinical study titled "Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients". The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevate...

What is the current status of trial NCT01941836?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2013-09. Estimated completion is 2014-11.

What conditions does trial NCT01941836 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT01941836?

The interventions under investigation include: Ezetimibe (DRUG), ETC-1002 (DRUG).

Who is sponsoring clinical trial NCT01941836?

This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01941836 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypercholesterolemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.